Denosumab Therapy for Postmenopausal Osteoporosis

Diagnostic Criteria and Treatment Guidelines

• The National Osteoporosis Foundation recommends pharmacologic treatment for all postmenopausal women with a T-score ≤ -2.5, without requiring prior treatment failures, as stated by the American College of Radiology 1, 4
• The patient has confirmed osteoporosis with a lumbar spine T-score of -2.5, which meets the WHO definition of osteoporosis (T-score ≤ -2.5), according to the Journal of the American College of Radiology 1, 3

Evidence Supporting Denosumab Use

• The USPSTF 2025 guidelines demonstrate that denosumab significantly reduces vertebral fractures (RR 0.32), nonvertebral fractures (RR 0.80), and hip fractures (RR 0.60) in postmenopausal women with osteoporosis, as reported in JAMA 2
• Denosumab is recognized as a highly effective first-line therapy for patients at high risk of fracture, without requiring bisphosphonate failure, according to the Journal of Clinical Oncology 6, 7

Critical Management Considerations

• The patient must receive adequate calcium (≥1000 mg daily) and vitamin D (800-1000 IU daily) supplementation before and during denosumab therapy, as recommended by Praxis Medical Insights 5
• If denosumab is ever discontinued, the patient MUST transition to another antiresorptive agent (typically a bisphosphonate) to prevent rebound bone loss and increased risk of multiple vertebral fractures, as stated in the Journal of Clinical Oncology and Praxis Medical Insights 5, 6

Common Pitfalls to Avoid

• Do not misinterpret MCG criteria as requiring bisphosphonate failure for patients with T-scores ≤ -2.5; this requirement applies only to osteopenic patients (T-scores -1.0 to -2.5), according to the Journal of the American College of Radiology and Praxis Medical Insights 1, 5
• Do not delay treatment based on absence of fragility fractures; a T-score ≤ -2.5 alone warrants treatment to prevent first fracture, as recommended by the Journal of the American College of Radiology and JAMA 1, 2